SCHEMBL2761684

SCHEMBL2761684

COC(=O)c1c(O)c2cccc(OCc3ccccc3)c2oc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.47
▸ MAOB P27338 4/20 0.46
▸ POLB P06746 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ CA5A P35218 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA5B Q9Y2D0 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762090 0.84 EGLN1 (0.47) LOXL2MAOBMAPTLMNAL3MBTL1
SCHEMBL2761617 0.83 EDNRA (0.54) MAOBALDH1A1CA9MAPTLMNA
SCHEMBL2780986 0.83 LOXL2 (0.44) LOXL2MAOBPOLBALDH1A1CA9
SCHEMBL27582379 0.78 CA12 (0.54) MAOBPOLBMEN1KMT2AALDH1A1
SCHEMBL2762010 0.76 L3MBTL1 (0.58) MAOBMEN1KMT2AALDH1A1TSHR
SCHEMBL2761681 0.76 MAOB (0.62) MAOBPOLBMEN1KMT2AALDH1A1
SCHEMBL7354719 0.76 CYP2C9 (0.58) LOXL2MAOBMEN1KMT2AALDH1A1
SCHEMBL8808593 0.76 LOXL2 (0.51) LOXL2MAOBPOLBMAPTKDM4E
SCHEMBL11933977 0.75 ALDH1A1 (0.45) LOXL2POLBALDH1A1CA12CA1
SCHEMBL2761993 0.75 ALDH1A1 (0.48) POLBMEN1KMT2AALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 LOXL2 1412/4885MAOB 424/4885POLB 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback